10hon MSN
The Highly Anticipated “Triple Agonist” Weight Loss Med Is Almost Here—What Doctors Say About It
Phase 3 clinical trial results are out now.
Life & Style on MSN
Why Experts Say This New Weight Loss Drug Could Be a Game Changer
From Ozempic to Wegovy to Mounjaro, injectable weight-loss drugs have become household names — and now there’s a new one ...
13hon MSN
Is Eli Lilly a Buy Before 2026?
Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.
Self Employed on MSN
Retatrutide targets three gut hormones
A next-generation weight-loss drug, retatrutide, is drawing interest for acting on three gut hormones ...
MedPage Today on MSN
GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025's Top Research
News and commentary from the endocrinology world ...
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...
With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...
Neurocrine Biosciences, Inc. ( NBIX) Discusses Progress and Strategy in Neurology and Obesity R&D Programs December 16, 2025 12:00 PM EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback